A Randomized, Double-blind, Placebo-controlled, Multicenter, Proof-of-concept, Phase IIA Study of MP1032 Plus Standard of Care vs Standard of Care in the Treatment of Hospitalized Participants With Moderate to Severe COVID-19

The purpose of this study is to evaluate the efficacy and safety of MP1032 with standard of care (SoC) verses placebo with SoC in hospitalized adults participants with moderate to severe coronavirus disease 2019 (COVID-19).

开始日期2021-10-19

申办/合作机构

Metriopharm AG

[+1]

NCT03706209 / Completed临床2期

A Phase II, Multicenter, Double-blind, Placebo-controlled, Efficacy and Safety Trial of Two Oral Doses (150 mg Bid / 300 mg Bid) of MP1032 in Male and Female Patients With Moderate-to-Severe Chronic Plaque Psoriasis

The primary objective of this trial is to evaluate the clinical efficacy and safety of two oral doses of MP1032 (150 mg bid and 300 mg bid) when taken for 12 weeks by patients with moderate-to-severe chronic plaque psoriasis.

开始日期2018-02-27

申办/合作机构

Metriopharm AG

[+1]

NCT02908347 / Completed临床2期

A Randomized (1:1), Double-blind, Parallel, Placebo-controlled Exploratory Pilot Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Systemic (po) Application of MP1032 in Patients With Moderate to Severe Chronic Plaque Psoriasis

This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks. Secondary endpoints to evaluate clinical parameters for psoriasis during the 6 week treatment period and a 4-week follow up will provide an opportunity to perform a first assessment of oral MP1032's clinical efficacy in the treatment of moderate to severe psoriasis.
The study population will consist of 44 enrolled (40 completed) patients with moderate to severe chronic plaque psoriasis. Patients must be able to provide written consent and meet all the inclusion criteria and none of the exclusion criteria.

开始日期2016-05-01

申办/合作机构

Metriopharm AG

[+1]

100 项与 Luminol sodium 相关的临床结果

登录后查看更多信息

100 项与 Luminol sodium 相关的转化医学

登录后查看更多信息

100 项与 Luminol sodium 相关的专利（医药）

登录后查看更多信息

项与 Luminol sodium 相关的文献（医药）

2024-04-01·Journal of colloid and interface science

Co3O4/NiCo2O4 heterojunction as oxygen evolution reaction catalyst for efficient luminol anode electrochemiluminescence

Article

作者: Zhao, Chulei ; Li, Wenjun ; Hong, Chenglin ; Zhang, Fuping ; Bao, Fuxi ; Ma, Chaoyun

Luminol has garnered significant attention from analysts as one of the most effective and commonly used electrochemiluminescence (ECL) reagents. However, the efficient luminescence of luminol anode is limited by the excitation of various reactive oxygen species (ROS). Typically, ROS are generated through co-reactive reagents and dissolved oxygen. Unfortunately, the former suffers from two drawbacks, namely biotoxicity and instability, while the latter cannot offer sufficient oxygen due to its limited solubility in aqueous solutions. Consequently, a low decomposition rate is usually obtained, leading to insufficient ROS. Therefore, there is an urgent need to develop efficient luminol anode systems. This study focuses on the use of zeolitic imidazolate framework-67 (ZIF-67) as a template, employing a controlled chemical etching method to create a ZIF-67/Ni-Co-layered double hydroxide (LDH). The intermediate composite is then annealed in air, resulting in the formation of a Co₃O₄/NiCo₂O₄ double-shelled nanobox (DSNB) heterostructure. Due to its structural advantages, the DSNB exhibits excellent electrocatalytic performance in the oxygen evolution reaction (OER). Furthermore, it was found that both the intermediates and products of OER can directly participate in the luminol chemiluminescence process, ultimately resulting in a 700-fold increase in the electrochemiluminescence (ECL) signal compared to an equal molar concentration of luminol solution. This work not only establishes the OER-mediated ECL system but also deepens the understanding of the relationship between ROS and luminol, providing a new pathway to study the luminol anodic ECL luminescence system.

2024-02-01·The Lancet regional health. Europe

Efficacy and safety of MP1032 plus standard-of-care compared to standard-of-care in hospitalised patients with COVID-19: a multicentre, randomised double-blind, placebo-controlled phase 2a trial

Article

作者: Ludescher, Beate ; Niedermaier, Michael ; Dings, Christiane ; Kaiser, Astrid ; Och, Katharina ; Sager, Petra ; Schmidt, Ivo ; Brysch, Wolfgang ; Schumann, Sara ; Lehr, Thorsten

Background:

SARS-CoV-2 infections still have a significant impact on the global population. The existing vaccinations have contributed to reducing the severe disease courses, decreasing hospitalisations, and lowering the mortality rate. However, due to the variability of COVID-19 symptoms, the emergence of new variants and the uneven global distribution of vaccines there is still a great need for new therapy options. One promising approach is provided by host-directed therapies. We assessed here the efficacy and safety of MP1032, a host-directed anti-viral/anti-inflammatory drug in hospitalised patients with moderate to severe COVID-19.

Methods:

In a randomised, double-blind, placebo-controlled, Phase IIa study, patients were randomised 2:1 to receive either 300 mg MP032 bid + Standard-of-Care (SoC) or placebo bid + SoC for 28 days. Eligible patients were ≥18 years old, tested positive for SARS-CoV-2, and had moderate to severe COVID-19 symptoms. The study spanned 20 sites in six countries (Bulgaria, France, Hungary, Italy, Romania, Spain), assessing disease progression according the NIAID scale as the primary outcome on day 14. Secondary objectives included disease progression (day 28), disease resolution (days 14 and 28), mortality rate, COVID-19 related parameters and safety. Exposure-response analyses were performed, linking MP1032 to COVID-19 biomarkers (eGFR, D-dimer).

Findings:

132 patients were enrolled to receive MP1032 + SoC (n = 87) or placebo + SoC (n = 45). The patients were all white or Caucasian with a mean (median) age of 60.5 (63) years. Overall, only 10 patients were vaccinated, 5 in each group. No significant risk difference of disease progression could be detected between groups on both day 14 (9.8% MP1032 vs. 11.6% placebo) and day 28 with MH common risk differences of -0.276% (95% CI, -11.634 to 11.081; p = 0.962) and 1.722% (95% CI, -4.576 to 8.019; p = 0.592), respectively.The treatment with MP1032 + SoC was safe and well-tolerated. Overall, 182 TEAEs including 10 SAEs were reported in 53.5% (46/86) of patients of the verum group and in 57.8% (26/45) of patients of the placebo group; the SAEs occurred in 5.8% (5/86) and 6.7% (3/45) of verum and placebo patients, respectively. None of the SAEs was considered as related.

Interpretation:

Despite the study's limitation in size and the variation in concurrent SoCs, these findings warrant further investigation of MP1032 as a host-directed anti-viral drug candidate.

Funding:

The study was funded by the COVID-19 Horizon Europe work programme and MetrioPharm AG.

2023-12-15·Biosensors & bioelectronics

A molecularly imprinted sensor for single-molecule detection of pesticide metabolite at the amol/L level sensitized by water-soluble luminol derivative encapsulated liposome via click reaction.

Article

作者: Li, Shiyu ; Ling, Jun ; Li, Jianping ; Liu, Guangyan ; Xu, Guobao ; Hou, Shili

A novel luminol derivative, 4-[(1,4-dioxo-1,2,3,4-tetrahydrophthalazin-5-yl)amino]-4-oxobut-2-enoic acid (ALD) with electrochemiluminescence intensity and stability characteristics similar to luminol, but higher solubility in near neutral solution, was designed and synthesized in this study. Using this derivative, a molecular imprinted electrochemiluminescence sensor (MIECLS) was prepared for the sensitive and selective determination of 2-amino-5-mercapto-1,3,4-thiadiazole (AMT), a metabolite of bismerthiazol, thiediazole copper, thiazole zinc, and other pesticides. The ALD probes encapsulated in liposomes are immobilized on the molecularly imprinted film by light-triggered click reaction, and the concurrent release of multiple probes allows for highly sensitive detection. In the AMT concentration range of 1.00 × 10^-18 - 5.00 × 10^-13 mol/L, the relation between ECL response and log AMT concentration is linear. With a detection limit of 5.25 × 10^-19 mol/L (about 4 - 6 molecules in 10 μL of the sample), the sensor allows for high sensitivity analysis of ultra-trace amounts of small organic compounds. In general, the ECL-based single-molecule detection technique proposed herein might be a promising alternative to fluorescence single-molecule detection.

项与 Luminol sodium 相关的新闻（医药）

2024-01-31

·BioSpace

MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19

Results of clinical trial CT-05 in 131 hospitalized patients with COVID-19 Trial data demonstrate that MetrioPharm´s lead compound MP1032 has comparable efficacy to remdesivir with several additional benefits Results have been published in The Lancet Regional Health – Europe Zurich, January 31, 2024 – MetrioPharm AG, a biotech company developing drugs for inflammatory and infectious diseases, announced today that results from its clinical trial CT-05 in hospitalized patients with moderate to severe COVID-19 have been published in the renowned journal The Lancet Regional Health – Europe. CT-05 was a multicenter, randomized double-blind, placebo-controlled Phase IIa trial in 6 European countries, supported by a EUR 7.9 million grant from the European Health Emergency Preparedness and Response Authority (HERA). A total of 131 COVID-19 patients were treated with Standard of Care (SoC) plus MetrioPharm’s lead compound MP1032 or with placebo. Patients treated with MP1032 (n=86) exhibited a lower mortality compared to those receiving placebo + SoC (n=45). The study demonstrated that in terms of early recovery from the disease and time to discharge, MP1032 exhibits comparable efficacy to remdesivir, with the additional benefit of excellent safety and oral availability. Moreover, the efficacy of MP1032 was enhanced when used in combination with anti-viral agents, including, but not limited to, remdesivir. ”Conducting this clinical trial amid the pandemic came with many challenges. This limited the possibility of obtaining statistical significance for the primary endpoints according to standard WHO protocols. These protocols had been defined with much larger studies in mind,” said MetrioPharm CSO and co-founder Dr. Wolfgang Brysch. “The results were nevertheless very strong. We have shown a clear therapeutic potential for our lead compound MP1032 in COVID-19. Most importantly, while most antiviral drugs target specific viruses, MP1032 acts as a host-directed therapy. This novel approach to antiviral therapies can potentially treat emerging and even completely novel viruses without prior adaptation, which is essential for future pandemic preparedness.” "An average of 2.4 days earlier discharge from hospital after 14 days of treatment with MP1032, an average of 4 days shorter ICU stay and faster recovery – these results alone are a great outcome for our trial of MP1032 in COVID-19,” said Thomas Christély, CEO of MetrioPharm. "These properties are currently being further investigated, as they would make MP1032 a very promising option for a broad first-line therapeutic and prophylactic treatment option to protect at-risk populations against new, emerging viruses. In addition, we have a strong rationale to suggest potential for the treatment of Long Covid which remains a problem for a large patient population. MP1032, with its host-directed mechanism of action, addresses four key drivers of this new indication: a persistent virus, immune mitochondrial dysregulation, micro-embolisms, and pulmonary fibrosis. Although our current development focus is on rare and orphan diseases, we will continue to develop MP1032 in a range of infectious diseases, some of which with pandemic potential, subject to further support from large public grants.” You can find MetrioPharm’s publication on MP1032 in patients with COVID-19 here. ### About MP1032 MP1032 is a unique small molecule targeting overshooting reactions of activated immune cells by addressing a central, natural metabolic process occurring in activated immune cells. The mitochondria of these cells react to the activation by boosting their energy metabolism, which in turn leads to the generation of reactive oxygen species (ROS) and an increase of intercellular pH. MP1032 is activated only by clusters of elevated pH and acts as an ROS scavenger, normalizing the pathologically increased ROS levels (oxidative stress). Once the pH returns to normal, the drug stops is no longer activated and working. This unique, self-regulating mechanism of action makes MP1032 a first-in-class anti-inflammatiory drug that reduces excessive ROS without interfering with the physiological ROS levels of other cells, that are essential for normal cell function, resulting in an excellent safety profile. About MetrioPharm MetrioPharm AG is a Swiss biotech company developing first-in-class auto-regulated immune modulators targeting the pathologically dysregulated mitochondrial metabolism in macrophages. MetrioPharm's platform of oral small molecules has demonstrated preclinical & clinical efficacy (three Phase II studies) in several inflammatory and infectious diseases with an excellent safety profile. As a monotherapy, MetrioPharm's lead candidate MP1032 produces therapeutic effects similar to corticosteroids (cortisone-based therapeutics), but without serious side effects. MP1032 has demonstrated synergistic/supra-additive effects in combination with an ultra-low dose (10% of the normal dose) of corticosteroids, demonstrating the potential to create a new class of "super corticosteroids" that are more effective and have no serious side effects. For more than 60 years, there have been no major advances in achieving such corticosteroid-sparing therapy and thereby reducing corticosteroid-specific side effects. In addition, MP1032 has demonstrated broad host-directed antiviral activity in preclinical studies against 6 tested COVID-19 variants and multiple influenza virus variants, as well as antibacterial activity against multiple bacterial strains. The Company is headquartered in Zurich and has a subsidiary for R&D activities in Berlin. About the European Commission funding This project has received funding from the European Union's Horizon Europe program under the HERA incubator. This funding program was launched in April 2021 to support urgently needed research and development to combat the corona virus and its variant across Europe. The grant agreement No. is 101046182. MetrioPharm's iMPact project is part of a broad range of European Commission research and innovation activities to combat the corona virus. The iMPact project was nominated for European Commission funding in July 2021, and the grant agreement was signed in November 2021. Forward-looking statements This press release contains forward-looking statements that involve risks and uncertainties and are consistent with MetrioPharm AG's assessment as of the date of this release. Such forward-looking statements are neither promises nor guarantees and are subject to numerous risks and uncertainties. No representations or warranty is made, and no reliance should be placed, expressively or impliedly, on the timeliness, accuracy or completeness of such data and information. Contacts MetrioPharm Corporate Communications & Press Relations T + 41 44 552 7198 E presse@metriopharm.com W akampion Dr. Ludger Wess / Ines-Regina Buth Managing Partners info@akampion.com Tel. +49 40 88 16 59 64 / Tel. +49 30 23 63 27 68 Funded by the European Union. Founding no. 101046182. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Commission. Neither the European Union nor the granting authority can be held responsible for them.

临床2期临床结果

2021-08-19

·BioSpace

Thomas Christély Joins Management of MetrioPharm AG as CEO

Thomas Christély to start as CEO of MetrioPharm AG on October 1, 2021 Dr. Wolfgang Brysch will accelerate expansion of clinical development as CSO & CMO ZURICH, Switzerland, Aug. 19, 2021 (GLOBE NEWSWIRE) -- MetrioPharm AG, a pharmaceutical company developing drugs for chronic inflammatory diseases, is expanding its management team. Effective October 1, 2021, Thomas Christély will take on the role as MetrioPharm’s Chief Executive Officer. Thomas Christély has comprehensive experience in the biotech and pharma industry as CEO, CFO and CBO in Europe and the US; he has successfully concluded more than 20 significant collaborations and licensing agreements with major international pharma and biotech companies, including AstraZeneca, Pfizer and Novartis. Most recently, as Managing Director and CFO, he led the successful development of the German pharmaceutical start-up MYR GmbH; in this role he was responsible for the sale of the company to Gilead Sciences Inc. in a transaction worth €1.15 billion plus a milestone payment of a further €300 million. His future responsibilities at MetrioPharm will include most notably business development and financing. Thomas Christély takes over these responsibilities from MetrioPharm co-founder and co-owner Dr. Wolfgang Brysch. Dr. Brysch previously performed these responsibilities together with his duties as Chief Scientific Officer and Chief Medical Officer. In addition to the Phase II study in the indication COVID-19, Dr. Brysch will lead the future expansion of MetrioPharm's development pipeline for the company’s lead compound MP1032. Rudolf Stäger, Chairman of the Board of Directors of MetrioPharm AG comments: "On behalf of the entire Board of Directors, I would like to thank Dr. Wolfgang Brysch for the excellent positioning of MetrioPharm AG until today, which has just been confirmed by the European Commission’s nomination to the list of HERA funded projects. At the same time, I am very pleased to welcome Thomas Christély to the company. With his profound experience in business development, he is extremely well suited to prepare the company for the next milestones. The new management structure will allow us to build on our excellent clinical work while enforcing our company’s growth." Dr. Wolfgang Brysch states: "As CSO and CMO, I will be able to fully focus on the scientific strategy and medical development of our lead compound in the future. Our goal is to rapidly bring MP1032 to market while simultaneously developing its full potential in additional indications. I am very much looking forward to intensifying the corporate growth of MetrioPharm AG together with Thomas Christély." AboutMetrioPharmAG MetrioPharm AG is a pharmaceutical development company focusing on drugs for chronic inflammatory diseases such as psoriasis, arthritis, and multiple sclerosis. Such chronic diseases pose the greatest individual health risk. The goal of MetrioPharm AG is to make the therapy of chronic inflammatory diseases more effective and more tolerable. We hope to achieve a healthspan expansion for patients: We want to stop the progression of chronic inflammatory diseases as early as possible and significantly prolong the healthy lifespan of millions of people. MetrioPharm was founded in 2007 with headquarters in Zurich. The company has its R&D activities in Berlin. AboutMP1032 MP1032 is a member of a new class of small molecule ROS scavengers that is targeted at activated macrophages and inflamed tissues. The molecule acts as a self-regulating modulator of cellular oxidative stress: due to its molecular structure, MP1032 is active when it is exposed to elevated levels of reactive oxygen species (ROS). The molecule changes from its inert state (inactive) to a deprotonated form (activated), in this process ROS are neutralized. Due to its self-regulated mode of activation, the effect of MP1032 is limited solely to the site of inflammation. MP1ß32 acts at the top of the inflammatory cascade and has demonstrated broad anti- inflammatory and anti-infective activity in animal models, as well as an excellent safety pro preclinical and clinical studies. Since 2021, MetrioPharm is testing MP1032 in an international Phase II clinical trial in the indication COVID-19. Forward-lookingstatements This press release contains forward-looking statements that involve risks and uncertainties and are consistent with MetrioPharm AGs assessment as of the date of this release. Such forward-looking statements are neither promises nor guarantees, but are subject to numerous risks and uncertainties, many of which are beyond MetrioPharm AGs control, that could cause actual results to differ materially from those contemplated in these forward-looking statements. MetrioPharm does not assume any obligation to update forward-looking statements with respect to changed expectations or new events, conditions or circumstances on which these statements are based. A liability or guarantee and, if applicable, claims for topicality, correctness and completeness of these data and information are excluded and cannot be derived either explicitly or impliedly. Contact Lia Petridou Corporate Communications &PressRelations T +49 (0) 30 33 84 395 53 F +49 (0) 30 33 84 395 99 E presse@metriopharm.com W

高管变更小分子药物合作

2021-07-29

·BioSpace

Global Roundup: Takeda and PeptiDream Expand CNS Collaboration

BioSpace Global Roundup, July 29 Takeda Pharmaceutical and Peptidream Inc., both of Japan, expanded a research collaboration and licensing agreement first struck in December 2020 to develop peptide-drug conjugates (PDCs) for several central nervous system (CNS) targets, which play important roles in chronic neurodegenerative diseases. The PDCs for neuromuscular diseases were first developed by PeptiDream. The companies said the latest collaboration expands the use of the TfR1 binding peptide ligands for CNS targets associated with neurodegeneration. When conjugated to various therapeutic payloads, peptide carriers that bind to TfR1 enable the transport of the payload across the blood-brain barrier, which significantly improves functional benefit. “Combining PeptiDream’s innovative peptide technology with Takeda’s strength in drug discovery and development, this collaboration aims to tackle longstanding bio-distribution challenges that have, to date, limited the ability to effectively treat many neuromuscular diseases,” Sarah Sheikh, Head of the Neuroscience Therapeutic Area Unit at Takeda said in a statement. Elsewhere around the globe: Saniona – Denmark-based Saniona received Orphan Drug Designation from the U.S. Food and Drug Administration for Tesomet, an investigational treatment for hypothalamic obesity. Saniona is planning two Phase IIb studies of Tesomet in the second half of this year, one in hypothalamic obesity and the other in Prader-Willi syndrome (PWS), for which Tesomet has already received orphan drug status. In a previous Phase II study in HO, adults receiving Tesomet demonstrated statistically significant reductions in body weight and improvements in waist circumference and glycemic control. These improvements were maintained during an additional 24-week open-label extension. NVIDIA – U.K.-based NVIDIA and King’s College London announced new details about an AI project using NVIDIA’s Cambridge-1 supercomputer. King’s College is using Cambridge-1 to build AI models that are able to generate synthetic brain images. The research will enable scientists to differentiate healthy brains from those that are diseased. Origin Therapeutics – Vancouver’s Origin Therapeutics Holdings launched this week with a focus on providing retail investors with exposure to a portfolio of diverse private companies in the psychedelics sector. Origin Therapeutics will invest in a diverse range of psychedelic companies that could include early-stage drug development companies, clinics, as well as other ancillary companies that help to push the industry forward. IMIDomics Inc. – Drug discovery company IMIDomics completed a $16.5 million Series A financing round. The funding will be used to fuel precision discovery efforts and accelerate technologies that are critical to the further development of new IMID treatments. IMIDomics’ Precision Discovery Platform combines and analyzes clinical, epidemiologic, and biomolecular data to uncover new insights about IMIDs including lupus, Crohn’s disease, rheumatoid arthritis, and ulcerative colitis. CARMAT – CARMAT’s artificial heart continues to be used across Europe. The France-based company announced the first Aeson bioprosthetic artificial heart was implanted in a patient in Germany. ERS Genomics – Ireland’s ERS Genomics struck a likening deal with Japan SLC, Inc. for its CRISPR/Cas9 patent portfolio. Japan SLC supports research organizations by providing animal models from its varied portfolio, including outbred, inbred, immunodeficient, congenic, hybrid, disease models and transgenic. The addition of CRISPR/Cas9 technology to the company’s toolbox will enable the expansion of its offering. Financial details of the agreement are not disclosed. Artios Pharma – U.K.-based Artios completed a £110 million (about $153 million) series C financing round. The funds will be used to advance its broad DDR-based platform and small molecule drug discovery capabilities for cancer. Accelex – London’s Accelex expanded its agreement with LGT Capital Partners to provide their cutting-edge SaaS platform to bring digitization to the regular extraction of critical financial information from a wide range of private markets investment documents. ProBioGen – Germany’s ProBioGen and Maryland-based ValenzaBio announced the initiation of a cell line development project involving the application of ProBioGen's proprietary GlymaxX technology. ValenzaBio's VB119 is a clinical-stage antibody for which ProBioGen will generate a new CHO-based expression system. Besides the CHO.RiGHT cell line development platform, ProBioGen will apply its ADCC modulating GlymaxX technology. GlymaxX enables a fine tuning of the fucose content of the antibody towards the originator molecule's fucose content. CN Bio – U.K.-based CN Bio, an organ-on-a-chip company, secured the licensing rights to a novel tool for modeling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University. The technology will be integrated into CN Bio’s PhysioMimix OOC range of single- and multi-organ MPS, enabling researchers to investigate the direct interaction between the microbiome and gut, and the wider effects of the microbiome on organs such as the liver and brain. ObsEva – Switzerland-based ObsEva and Organon entered into a licensing agreement. New Jersey-based Organon will license the rights to ebopiprant, an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions. ObsEva received $500 million in upfront payments and is eligible for an additional $385 million in sales-based milestones, plus royalties, should ebopiprant be approved by the FDA. Byondis BV – Netherlands-based Byondis and Germany’s Glycotope entered into a platform access agreement to discover and develop antibodies that target specific tumor-associated protein/carbohydrate combined glyco-epitopes (GlycoTargets). Glycosylation is strongly altered in cancer cells, reflecting the drastic changes in tumor metabolism, which results in new, highly tumor-specific epitopes (GlycoTargets). Specific antibodies against these GlycoTargets might be highly cancer-specific and have the potential to target a broad range of oncology indications. AC Immune SA – AC Immune, based in Switzerland, is acquiring Affiris’ portfolio of therapeutics targeting alpha-synuclein (a-syn). The deal includes PD01, a clinically-validated active vaccine candidate for the treatment of Parkinson’s disease. Additionally, the acquisition included Affiris’ available cash, valued at $5 million. DiosCURE Therapeutics – Germany’s DiosCURE signed a licensing agreement with the University of Bonn, University Hospital Bonn, Scripps Research and Macrostruct Holding & Consulting AB, for a broad suite of intellectual property, including the single-domain antibodies, DIOS-202, DIOS-203 and DIOS-301. The assets are in preclinical development. They are multivalent single-chain antibodies with unique molecular modes-of-action to inactivate SARS-CoV-2 virions. MetrioPharm AG – Switzerland-based MetrioPharm has been nominated to receive funding under the HERA Incubator from the European Commission. The company is developing drugs for chronic inflammatory diseases. MetrioPharm’s lead compound MP1032 is being assessed against COVID-19. MP1032 has demonstrated strong immunomodulatory and specific antiviral properties against SARS-CoV-2 in preclinical studies.

合作抗体孤儿药疫苗小分子药物

100 项与 Luminol sodium 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	D05A	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床2期	美国	Metriopharm AG	2021-10-19
新型冠状病毒感染	临床2期	保加利亚	Metriopharm AG	2021-10-19
新型冠状病毒感染	临床2期	法国	Metriopharm AG	2021-10-19
新型冠状病毒感染	临床2期	匈牙利	Metriopharm AG	2021-10-19
新型冠状病毒感染	临床2期	意大利	Metriopharm AG	2021-10-19
新型冠状病毒感染	临床2期	罗马尼亚	Metriopharm AG	2021-10-19
新型冠状病毒感染	临床2期	西班牙	Metriopharm AG	2021-10-19
斑块状银屑病	临床2期	德国	Metriopharm AG	2016-05-01
银屑病	临床2期	-	Metriopharm AG	-
幼年型关节炎	临床1期	-	Metriopharm AG	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04932941 (Literature) 人工标引	临床2期	新型冠状病毒感染	131	MP1032+Standard-of-Care	夢鏇遞獵顧襯醖醖顧構(製網窪鏇願遞選願襯鏇) = 顧構鑰蓋遞網顧廠醖窪廠構醖蓋網選窪廠願廠 (築鬱餘鏇膚遞餘壓憲鑰 ) 更多	积极	2023-12-06
				placebo +standard-of-care	夢鏇遞獵顧襯醖醖顧構(製網窪鏇願遞選願襯鏇) = 齋範願餘鹽顧憲選鏇築廠構醖蓋網選窪廠願廠 (築鬱餘鏇膚遞餘壓憲鑰 ) 更多
NCT04932941 (CTgov)	临床2期	新型冠状病毒感染	132	MP1032 (MP1032 300mg + SoC)	窪獵範獵觸窪選衊選簾(獵膚繭窪膚膚襯廠壓齋) = 壓醖獵願積鬱蓋廠積鹽獵簾鹽廠餘積積夢壓鑰 (鏇鹽觸獵鏇選範淵獵繭, 積憲遞遞醖簾網鏇廠鹹 ~ 簾憲簾遞鏇膚顧觸膚鏇) 更多	-	2023-06-29
				Placebo (Placebo + SoC)	窪獵範獵觸窪選衊選簾(獵膚繭窪膚膚襯廠壓齋) = 觸網觸築觸衊醖獵醖遞獵簾鹽廠餘積積夢壓鑰 (鏇鹽觸獵鏇選範淵獵繭, 衊鬱廠鬱築範鬱鏇繭壓 ~ 獵積築餘獵鬱製夢製衊) 更多